Sotrovimab News and Research

RSS
SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

SARS-CoV-2 Delta-Omicron recombinant identified in a transplant patient treated with Sotrovimab

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Novel monoclonal antibody found to have substantial neutralizing capacity against SARS-CoV-2 Omicron variant

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers evaluate predictors for mortality in hospitalized COVID-19 patients

Researchers evaluate predictors for mortality in hospitalized COVID-19 patients

The effects of anti-SARS-CoV-2 monoclonal antibodies on pregnant and postpartum women

The effects of anti-SARS-CoV-2 monoclonal antibodies on pregnant and postpartum women

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Research identifies differences between Omicron lineages BA.1 and BA.2

Research identifies differences between Omicron lineages BA.1 and BA.2

Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages

Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages